Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00835926 · ClinicalTrials.gov registry record · Phase 4
A Study to Evaluate the Safety and Immune Responses to Fluzone® Vaccination
A Phase 4 study, sponsored by Sanofi Pasteur, a Sanofi Company.
- Completed
- Registry status
- Phase 4
- Development phase
- 121
- Enrollment target
NCT00835926 is a Phase 4 study that has completed, run by Sanofi Pasteur, a Sanofi Company. The registered enrollment target is 121 participants.
The verdict
NCT00835926, a Phase 4 study, has completed, sponsored by Sanofi Pasteur, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 121 participants
- Enrollment target
Study Summary
To describe the safety during days 0 to 21 following injection of the 2003-2004 formulation of the inactivated, split-virion influenza vaccine Fluzone® in subjects aged 18-59 years and subjects aged ≥ 60 years. To describe the immune response at 21 days following injection of the 2003-2004 formulation of the inactivated, split-virion influenza vaccine Fluzone®, in subjects aged 18-59 years and subjects aged ≥ 60 years.
Interventions
- BIOLOGICAL Influenza virus vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 121 participants |
| Start Date | 2003-07 |
| Est. Completion | 2003-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00835926
The ClinicalTrials.gov registry entry for NCT00835926 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 121 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi Pasteur, a Sanofi Company, which has 153 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Influenza virus vaccine is the first listed.
NCT00835926 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00835926 about?
NCT00835926 is a clinical study titled "A Study to Evaluate the Safety and Immune Responses to Fluzone® Vaccination". To describe the safety during days 0 to 21 following injection of the 2003-2004 formulation of the inactivated, split-virion influenza vaccine Fluzone® in subjects aged 18-59 years and subjects aged ≥ 60 years. To describe the immune response at 21 days following injection of the 2003-2004 formulat...
What is the current status of trial NCT00835926?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 121 participants. The study started on 2003-07. Estimated completion is 2003-09.
What interventions are being tested in trial NCT00835926?
The interventions under investigation include: Influenza virus vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00835926?
This trial is sponsored by Sanofi Pasteur, a Sanofi Company, which has 153 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.